News and Announcements
Bionomics New Alzheimer’s Drug Candidate
- Published December 14, 2012 4:42PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bionomics Limited (ASX:BNO, ADR:BMICY) has identified a novel compound with promising properties as a potential new treatment for Alzheimer’s disease. Following validation in preclinical models of memory deficit in Alzheimer’s disease, Bionomics has formally nominated BNC375 as its drug candidate. BNC375 is currently on a dual track, as Bionomics prepares for both clinical trials and strategic partnering.
BNC375 is proprietary to Bionomics and is a positive allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), an important target for the improvement of memory and learning deficits that occur in illnesses like Alzheimer’s disease.
——-
To view the full article, please click the link below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
